Methods of Improving Cancer Immunotherapy

Abstract

Researchers at the University of California, Davis have developed methods that combine immunotherapeutic agents with dual inhibitors to enhance cancer treatment efficacy and prolong patient survival.

Full Description

This technology provides methods for preventing, suppressing, or treating cancer by administering at least one immunotherapeutic agent alongside a dual inhibitor of COX-2 and soluble epoxide hydrolase (sEH), or an sEH inhibitor alone. The approach can include immune checkpoint inhibitors targeting PD-1, PD-L1, LAG-3, or CTLA-4, and may be combined with chemotherapeutic agents or dietary modifications involving high omega-3 or omega-6 intake. These methods are applicable to a wide range of cancers including bladder, ovarian, breast, and lung cancers, aiming to improve immunotherapy effectiveness and patient outcomes.

Applications

• Oncology therapies targeting bladder, breast, ovarian, lung, and other cancers. 
• Combination cancer immunotherapies. 
• Pharmaceutical development of dual COX-2 and sEH inhibitors. 
• Immune checkpoint inhibitor therapies. 
• Adjunct cancer treatment involving nutritional interventions.

Features/Benefits

• Enhances the effectiveness of existing immunotherapies. 
• Prolongs survival in cancer patients. 
• Modulates immune response through dual inhibition of COX-2 and sEH. 
• Enables flexible treatment by combining immune checkpoint inhibitors with chemotherapy and dietary approaches. 
• Applies treatment strategies across multiple cancer types. 
• Improves immunotherapy response rates in cancers with high non-responsiveness (e.g., bladder cancer). 
• Reduces toxicity associated with immunotherapy. 
• Overcomes resistance to immune checkpoint inhibitors. 
• Provides alternative options for patients unresponsive to existing treatments.

Patent Status